Swati Spentose Pvt Ltd
SWATI is a global research-oriented company with a vision to take science to market. With a distinguished history spanning over fifty years, our commitment extends beyond expanding our product range; for the past twenty-five years, we have dedicated ourselves to addressing neglected diseases. The company has garnered global FDA accreditations from numerous regulatory bodies, including the USFDA, EDQM, and FDA authorities from Russia, China, Japan, Mexico, Brazil, the UK, Australia, and Canada.
SWATI is at the forefront of pioneering research in polysaccharides and is currently engaged in negotiations with the Massachusetts Institute of Technology (MIT) to drive significant global advancements in biotechnology, specifically targeting disease areas where no current treatments are available.
Our Purpose
Our distinguished record in research, extensive global FDA accreditations, and strategic collaborations with leading international universities underscore its commitment to providing groundbreaking solutions to complex global health issues.
SWATI’S journey epitomizes its core identity and heritage as a pioneering, globally-focused research-driven organization. With a vision to translate scientific advancements into market-ready solutions, the company has demonstrated remarkable resilience by navigating a 20-year path to deliver its innovative products to patients in need.
SWATI has achieved groundbreaking success on a global scale in addressing rare and neglected diseases related to women’s bladder health. Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a chronic condition characterized by bladder pain, pressure, and discomfort. It often leads to frequent and urgent need to urinate, and can significantly impact a person’s quality of life.
Diseases such as IC are often neglected by the global health community and are characterized by limited research and development funding, scarce access to affordable treatments, and inadequate healthcare resources. Our mission is unwavering in its dedication to tackling global health challenges by advancing novel treatments for diseases that currently have no effective solutions.
Our distinguished record in research, extensive global FDA accreditations, and strategic collaborations with leading international universities underscore its commitment to providing groundbreaking solutions to complex global health issues.
SWATI’S journey epitomizes its core identity and heritage as a pioneering, globally-focused research-driven organization. With a vision to translate scientific advancements into market-ready solutions, the company has demonstrated remarkable resilience by navigating a 20-year path to deliver its innovative products to patients in need.
SWATI has achieved groundbreaking success on a global scale in addressing rare and neglected diseases related to women’s bladder health. Interstitial cystitis (IC), also known as bladder pain syndrome (BPS), is a chronic condition characterized by bladder pain, pressure, and discomfort. It often leads to frequent and urgent need to urinate, and can significantly impact a person’s quality of life.
Diseases such as IC are often neglected by the global health community and are characterized by limited research and development funding, scarce access to affordable treatments, and inadequate healthcare resources. Our mission is unwavering in its dedication to tackling global health challenges by advancing novel treatments for diseases that currently have no effective solutions.
Leaders
Mr. Vishal N. Jajodia
Managing Director
Mr. Vishal Jajodia is the new age social entrepreneur specializing in areas of neglected and orphan diseases. He has 25 years of experience in the industry and has held important positions in export promotion councils under the ministry of commerce and has participated in policy forming committees. He has had a drug discover informatics company during the early 2000’s and has done several projects related to proteomics, genomics and drug target identification using artificial intelligence and machine learning tools.
Currently his flagship company M/s Swati Spentose Pvt. Ltd. with a manufacturing base out of Vapi has invested over USD 20 million across manufacturing and research platforms, including launching and promoting new health solutions in debilitating diseases in urology and nephrology, with research sponsored at prestigious Mt Sinai School of Medicine, New York – USA.
They have for the first time in the world, launched a generic drug where the treatment cost was USD 25000, and only available in the US for over 20 years and now have made the same available in India and 4 more countries at approximately 1200 USD (5% of the originator). They also currently hold patents on diseases related to kidney where presently there are no medicines available to suffering patients. They are also working on rare diseases like Mucopolysaccharidosis which is bone inflammation leading to dwarfism.
We are committed to harnessing new business models of social entrepreneurship where we develop community shared value formats as originally conceptualized by global thought leaders like Michael Porter.
We also have several environmental initiatives, again harnessing community shared value business models, across corporate farming, water conservation and environmentally sustainable industrialization in symbiotic relation with villagers leading to rubinazation (rural urbanization)
Ms. Swati Jajodia
Chief Executive Officer
Ms. Swati Jajodia is the head of Swati Spentose’ s key marketing efforts, responsible for the meteoric rise of the company. Hailing from an illustrious textile family, she is now deeply involved in the pharmaceutical business, which was destined to happen after her marriage to Mr. Vishal Jajodia. Starting her career at the age of 16 while pursuing her studies in Sydenham college, she realized that work was her foremost passion, and that business was deeply entwined in her DNA . After graduating with a B. Com. Degree, she went on to pursue law from the Government Law College (Mumbai), and followed it up with an MBA in Finance from the Newport University, California.
Having been brought up in a very disciplined environment, while at the same time growing with virtues of everyday existence like integrity and humility, she started operating the family pharmaceutical business in a similar manner, thereby catapulting the company as one of the most reliable and honest organizations to work with a conscious vision of providing a level playing field to women, she groomed the young as well as senior women in the organization for top-most positions within the company, thereby empowering them to lead various segments of business which they were a part of.
Swati had a belief since many years that “Every suffering patient should be provided a solution at affordable prices if the same is available anywhere in the world“. She believed in it so much that it became a reality with the launch of COMFORA, a treatment for Interstitial Cystitis, a neglected and orphan disease across the world. The Jajodia’s have indigenously researched and manufactured this product for India and for the rest of the world. This unrivalled passion is the driving force to work hard and make their company name synonymous with a research driven, premier solution provider for orphan and neglected diseases.
Our History
The company’s origins can be traced back to Kolkata in 1952, where the Euresian Group commenced its operations as a trader in pharmaceuticals, fine chemicals, and steel. In 1970, the late Mr. Narayan Prasad Jajodia established a business in Mumbai and quickly became a leading supplier to top Indian pharmaceutical companies, including Sun Pharma, Lupin, Microlabs, Cipla, Ranbaxy, Macleods, and IPCA Labs.
In 1996, Mr. Jajodia’s son, Vishal, assumed leadership and directed a strategic transformation of the company, evolving it from a distribution-focused enterprise into a research and innovation-driven organization with a strong emphasis on manufacturing and R&D.
1970
Founder & Managing Director, the late Mr. Narayan Prasad Jajodia established the Euresian Group in Mumbai
1993
Mr. Vishal Jajodia joined the company, heading its distribution division
1997
The first manufacturing unit, Alcon Biosciences PVT LTD was is up in Vapi, Gujarat, India
1998
The first R&D lab is set up in Mumbai
2005
The inception of Swati Spentose PVT LTD a company specializing in research and manufacturing for regulatory markets.
2006
A world class polysaccharide manufacturing facility is set up in Vapi, Gujarat, India
2008
A WHO GMP site for steroids and hormones is set up
2009
SWATI launches the first generic for Pentosan in the world
2016
First USFDA inspection for polysaccharides and other products at Unit 1
Recognition
Swati Spentose Pvt Ltd has won the APTAR “Innovation of the year award – 2021”
Swati Spentose Pvt. Ltd. was honored with the APTAR “Innovation of the Year Award – 2021” during IDMA’s 60th Diamond Jubilee celebrations, organized by India’s premier pharmaceutical body. This prestigious award, presented by the Health Minister Mansukh Mandaviya, underscored the event’s focus on celebrating Indian innovation in pharmaceuticals.
Crackling Chemistry, Marwar
Vishal and Swati Jajodia are hand-in-glove with each other to deliver responsible medication and better healthcare, especially for diseases that are orphaned, ignored or neglected. MARWAR meets the duo to find out more about their work and life.